Chapter 1. Research Background
1.1. Research Objectives
1.2. Market Definition
1.3. Research Scope
1.3.1. Market Segmentation by Service Type
1.3.2. Market Segmentation by Therapeutic Area
1.3.3. Market Segmentation by End User
1.3.4. Market Segmentation by Geography
1.3.5. Analysis Period
1.3.6. Market Data Reporting Unit
1.4. Key Stakeholders
Chapter 2. Research Methodology
2.1. Secondary Research
2.2. Primary Research
2.2.1. Breakdown of Primary Research Respondents
2.2.1.1. By region
2.2.1.2. By industry participants
2.2.1.3. By company type
2.3. Market Size Estimation
2.4. Market Breakdown and Data Triangulation
2.5. Assumptions for the Study
Chapter 3. Executive Summary
Chapter 4. Introduction
4.1. Market Segmentation
4.1.1. Overview by Service Type
4.1.1.1. Early-phase development services
4.1.1.1.1. Discovery studies
4.1.1.1.2. Chemistry, manufacturing & control (CMC)
4.1.1.1.3. Preclinical services
4.1.1.2. Clinical research services
4.1.1.2.1. Phase I clinical research services
4.1.1.2.2. Phase II clinical research services
4.1.1.2.3. Phase III clinical research services
4.1.1.2.4. Phase IV clinical research services
4.1.1.3. Laboratory services
4.1.1.3.1. Bioanalytical testing services
4.1.1.3.2. Analytical testing services
4.1.1.4. Consulting service
4.1.2. Overview by Therapeutic Area
4.1.2.1. Oncology
4.1.2.2. Cardiovascular
4.1.2.3. Central nervous system (CNS)
4.1.2.4. Diabetes
4.1.2.5. Respiratory
4.1.2.6. Others
4.1.3. Overview by End User
4.1.3.1. Pharmaceutical and biopharmaceutical companies
4.1.3.2. Medical device companies
4.1.3.3. Others
4.2. Market Dynamics
4.2.1. Trends
4.2.2. Drivers
4.2.2.1. Impact analysis of drivers on market forecast
4.2.3. Restraints
4.2.3.1. Impact analysis of restraints on market forecast
4.2.4. Opportunities
4.3. Porter’s Five Forces Analysis
Chapter 5. Market Size and Forecast by Service Type
5.1. Early-Phase Development Services
5.1.1. Discovery Studies
5.1.2. Chemistry, Manufacturing & Control (CMC)
5.1.3. Preclinical Services
5.2. Clinical Research Services
5.2.1. Phase I Clinical Research Services
5.2.2. Phase II Clinical Research Services
5.2.3. Phase III Clinical Research Services
5.2.4. Phase IV Clinical Research Services
5.3. Laboratory Services
5.3.1. Bioanalytical Testing Services
5.3.2. Analytical Testing Services
5.4. Consulting Service
Chapter 6. Market Size and Forecast by Therapeutic Area
6.1. Oncology
6.2. Cardiovascular
6.3. Central nervous system (CNS)
6.4. Diabetes
6.5. Respiratory
6.6. Others
Chapter 7. Market Size and Forecast by End User
7.1. Pharmaceutical and Biopharmaceutical Companies
7.2. Medical Device Companies
7.3. Others
Chapter 8. Market Size and Forecast by Geography
8.1. North America Contract Research Organization Market
8.1.1. By Type
8.1.2. By Therapeutic Area
8.1.3. By End User
8.1.4. By Country-The U.S, and Canada
8.2. Europe Contract Research Organization Market
8.2.1. By Type
8.2.2. By Therapeutic Area
8.2.3. By End User
8.2.4. By Country –Germany, France, U.K and Rest of Europe
8.3. Asia-Pacific Contract Research Organization Market
8.3.1. By Type
8.3.2. By Therapeutic Area
8.3.3. By End User
8.3.4. By Country -China, Japan, India, Australia and Rest of Asia-Pacific
8.4. Latin America Contract Research Organization Market
8.4.1. By Type
8.4.2. By Therapeutic Area
8.4.3. By End User
8.4.4. By Country – Brazil and Rest of Latin America
8.5. Middle East & Africa Contract Research Organization Market
8.5.1. By Type
8.5.2. By Therapeutic Area
8.5.3. By End User
Chapter 9. Competitive Landscape
9.1. Competitive Analysis of Key Players
9.2. Global Strategic Developments
Chapter 10. Company Profiles
10.1. Laboratory Corporation of America Holdings
10.1.1. Business Overview
10.1.2. Product and Service Offerings
10.1.3. Key Financial Summary
10.1.4. Strategic Growth Plan
10.2. Quintiles IMS Holdings, Inc.
10.2.1. Business Overview
10.2.2. Product and Service Offerings
10.2.3. Key Financial Summary
10.2.4. Strategic Growth Plan
10.3. PAREXEL International Corporation
10.3.1. Business Overview
10.3.2. Product and Service Offerings
10.3.3. Key Financial Summary
10.3.4. Strategic Growth Plan
10.4. Charles River Laboratories, Inc.
10.4.1. Business Overview
10.4.2. Product and Service Offerings
10.4.3. Key Financial Summary
10.4.4. Strategic Growth Plan
10.5. Pharmaceutical Product Development, LLC
10.5.1. Business Overview
10.5.2. Product and Service Offerings
10.5.3. Key Financial Summary
10.5.4. Strategic Growth Plan
10.6. ICON plc
10.6.1. Business Overview
10.6.2. Product and Service Offerings
10.6.3. Key Financial Summary
10.6.4. Strategic Growth Plan
10.7. PRA Health Sciences
10.7.1. Business Overview
10.7.2. Product and Service Offerings
10.7.3. Key Financial Summary
10.7.4. Strategic Growth Plan
10.8. inVentiv Health, Inc.
10.8.1. Business Overview
10.8.2. Product and Service Offerings
10.8.3. Key Financial Summary
10.8.4. Strategic Growth Plan
*Note: Key financial summary and strategic growth plan will be provided on best effort basis and is subject to availability during primary and secondary research.
Chapter 11. Appendix
11.1. Abbreviations
